# Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).

> **NCT02475733** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 83 (actual)

## Conditions studied

- Complicated Intra-abdominal Infections

## Interventions

- **DRUG:** Ceftazidime -avibactam
- **DRUG:** Meropenem
- **DRUG:** Metronidazole

## Key facts

- **NCT ID:** NCT02475733
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-01
- **Primary completion:** 2017-06-01
- **Final completion:** 2017-06-01
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2018-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02475733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02475733, "Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02475733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*